Drug Profile
Endoxifen - Atossa Therapeutics
Alternative Names: (Z)-endoxifenLatest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator Atossa Genetics
- Developer Atossa Therapeutics; Weill Cornell Medicine
- Class Antineoplastics; Methylamines; Phenyl ethers; Small molecules; Stilbenes
- Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Breast cancer; Ductal carcinoma; HER2 negative breast cancer
- Clinical Phase Unknown Ovarian cancer
- Preclinical Triple negative breast cancer
- No development reported Gynaecomastia
Most Recent Events
- 14 Feb 2024 Phase-II clinical trials in Ductal carcinoma in USA (PO) (NCT06075953)
- 06 Jul 2023 Atossa Therapeutics and Weill Cornell Medicine agree to co-develop endoxifen for Triple negative breast cancer
- 06 Jul 2023 Preclinical trials in Triple-negative-breast-cancer in USA (unspecified route) (Atossa Therapeutics Pipeline, April 2024)